ArticleDiscover oncology2026
An epithelial mesenchymal transition associated gene signature stratifies risk of ulcerative colitis associated colorectal cancer.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients with long-standing ulcerative colitis (UC) are at increased risk of developing colitis-associated colorectal cancer (UC-CRC). However, the molecular transition from chronic inflammation to neoplasia remains incompletely defined, and biomarkers for high-risk disease are still lacking.
methodsTranscriptomic datasets from UC and CRC cohorts were analyzed independently to identify reproducible transcriptional alterations. Differential expression and pathway enrichment analyses were followed by stepwise prioritization of candidate genes based on expression in UC-associated neoplasia, prognostic relevance in CRC, and classification performance. Receiver operating characteristic analysis and composite z-score modeling were used to evaluate signature performance, whereas gene co-expression analysis and single-sample gene set enrichment analysis were used to examine its biological context.
resultsEpithelial-mesenchymal transition (EMT) emerged as a consistently enriched pathway among upregulated genes in UC and CRC. Intersection of EMT-associated genes identified 24 shared candidates, of which 14 were significantly upregulated in UC-associated neoplasia compared with quiescent UC and showed consistent upregulation across independent active UC datasets. These genes showed strong discriminatory performance (AUC > 0.85), and Random Forest analysis further refined a seven-gene panel (FAP, TIMP1, COL12A1, CALU, INHBA, SPP1, and CTHRC1). A composite z-score derived from this panel distinguished neoplastic from quiescent UC and showed a stepwise increase across disease states. Functional analyses linked the signature to EMT, hypoxia, angiogenesis, coagulation, and inflammatory signaling.
conclusionsThis study identified a seven-gene EMT-associated signature linked to UC-associated neoplastic transformation. The signature may support molecular risk stratification in UC and provides a framework for future validation in surveillance settings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.